Cellular Therapy for Fanconi Anemia: The Past, Present, and Future

被引:16
|
作者
MacMillan, Margaret L. [1 ]
Hughes, Mark R. [2 ]
Agarwal, Suneet [3 ,4 ,5 ,6 ,7 ]
Daley, George Q. [3 ,4 ,5 ,6 ,7 ]
机构
[1] Univ Minnesota, Dept Pediat, Div Pediat Hematol Oncol & Blood & Marrow Transpl, Blood & Marrow Transplant Program, Minneapolis, MN 55455 USA
[2] Appl Genom Technol Ctr Michigan, Genesis Genet Inst, Detroit, MI USA
[3] Childrens Hosp Boston, Howard Hughes Med Inst, Manton Ctr Orphan Dis Res, Stem Cell Transplantat Program,Div Pediat Hematol, Boston, MA USA
[4] Dana Farber Canc Inst, Boston, MA 02115 USA
[5] Brigham & Womens Hosp, Div Hematol, Boston, MA 02115 USA
[6] Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA
[7] Harvard Stem Cell Inst, Boston, MA USA
关键词
BONE-MARROW-TRANSPLANTATION; PLURIPOTENT STEM-CELLS; APLASTIC-ANEMIA; DONORS; CYCLOPHOSPHAMIDE; IRRADIATION; DISEASE; BLOOD; ENGRAFTMENT; GENERATION;
D O I
10.1016/j.bbmt.2010.11.027
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Allogeneic hematopoietic cell transplantation (HCT) remains the only proven curative therapy for the hematologic manifestation of Fanconi anemia (FA). Over the past 2 decades, major advances have been made such that transplant outcomes have markedly improved. With the development of in vitro fertilization and preimplantation genetic diagnosis, HLA-matched sibling donor umbilical blood transplantation may be an option for more patients with FA. Recently, the use of pluripotent stem cells has been explored as a novel approach to model the hematopoietic developmental defects in FA, and to provide a potential source of autologous stem cells that can be genetically manipulated and used to generate corrected hematopoietic progenitors. Biol Blood Marrow Transplant 17: S109-S114 (2011) (C) 2011 American Society for Blood and Marrow Transplantation
引用
收藏
页码:S109 / S114
页数:6
相关论文
共 50 条
  • [41] MOLECULAR AND CELLULAR BIOLOGY OF FANCONI ANEMIA
    STRATHDEE, CA
    BUCHWALD, M
    AMERICAN JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 1992, 14 (02): : 177 - 185
  • [42] Fanconi anemia:: cellular and molecular features
    Mace, G.
    Briot, D.
    Guervilly, J. -H.
    Rosselli, F.
    PATHOLOGIE BIOLOGIE, 2007, 55 (01): : 19 - 28
  • [43] The Past, Present and Future of Cardiac Resynchronization Therapy
    O'Brien, Thomas
    Park, Myung-Soo
    Youn, Jong-Chan
    Chung, Eugene S.
    KOREAN CIRCULATION JOURNAL, 2019, 49 (05) : 384 - 399
  • [44] Androgen deprivation therapy: past, present and future
    Schroeder, F.
    Crawford, E. D.
    Axcrona, K.
    Payne, H.
    Keane, T. E.
    BJU INTERNATIONAL, 2012, 109 : 1 - 12
  • [45] Cardiac resynchronization therapy - Past, present and future
    Yu, CM
    JOURNAL OF CARDIAC FAILURE, 2005, 11 (09) : S258 - S259
  • [46] Epigenetic therapy of cancer: past, present and future
    Christine B. Yoo
    Peter A. Jones
    Nature Reviews Drug Discovery, 2006, 5 : 37 - 50
  • [47] Adoptive cell therapy: past, present and future
    Cohen, Jonathan E.
    Merims, Sharon
    Frank, Stephen
    Engelstein, Roni
    Peretz, Tamar
    Lotem, Michal
    IMMUNOTHERAPY, 2017, 9 (02) : 183 - 196
  • [48] Thyroid hormone therapy: past, present, and future
    David S. Cooper
    Leonidas H. Duntas
    Endocrine, 2019, 66 : 1 - 2
  • [49] The Past, Present and Future of POP and Physical Therapy
    Rhonda K. Kotarinos
    Elizabeth Kotarinos
    Current Obstetrics and Gynecology Reports, 2014, 3 (3) : 180 - 185
  • [50] Past, Present, and Future of Lipid Resuscitation Therapy
    Fettiplace, Michael R.
    Weinberg, Guy
    JOURNAL OF PARENTERAL AND ENTERAL NUTRITION, 2015, 39 : 72S - 83S